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Differential expression of immune 
checkpoint Modulators on In Vitro 
Primed cD4+ and cD8+ T cells
Nina C. Sabins*, Benjamin C. Harman, Linda R. Barone, Shixue Shen and  
Sandra Santulli-Marotto
Biologics Research, Janssen R&D, Spring House, PA, USA
PD-1, TIM-3, and LAG-3 are molecules shown to have immune modulatory properties, 
and although initially classified as indicators of T cell hyporesponsiveness, it has become 
clear that they are also associated with the normal course of T cell activation. Functional 
studies have focused mainly on CD8+ T cells during chronic inflammation due to interest 
in co-opting the cellular immune response to eliminate viral or cancerous threats; how-
ever, there remains a relative lack of data regarding the expression of these molecules on 
CD4+ T cells. Here, we report that expression of the immune checkpoint (IC) molecules 
PD-1, LAG-3, and TIM-3 are differentially expressed on CD4+ and CD8+ T cells in the 
allogeneic response resulting from a mixed lymphocyte reaction. In these studies, PD-1 
expression is higher on CD4+ T cells compared to CD8+ T cells. In contrast, TIM-3 is 
expressed at higher levels on CD8+ T cells compared to CD4+ T cells with an apparent 
reciprocity in that PD-1+ CD4+ T cells are frequently TIM-3lo/−, while TIM-3-expressing 
CD8+ T cells are largely PD-1lo/−. In addition, there is a decrease in the frequency of 
TIM-3+ CD4+ cells producing IFN-γ and IL-5 compared to TIM-3+ CD8+ cells. Lastly, the 
memory T cell phenotype within each IC-expressing subset differs between CD4+ and 
CD8+ T cells. These findings highlight key differences in IC expression patterns between 
CD4+ and CD8+ T cells and may allow for more effective therapeutic targeting of these 
molecules in the future.
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inTrODUcTiOn
T cells exposed to chronic antigen stimulation, particularly in the context of viral infection or 
the tumor microenvironment, are characterized as exhausted upon loss of proliferative potential, 
cytokine production, and cytotoxicity (1). Accompanied by progressive loss of function, these cells 
also acquire an altered phenotype with accumulated expression of what have been classified as 
immune checkpoint (IC) molecules, such as PD-1, TIM-3, and LAG-3. Ligand binding to PD-1 and 
TIM-3 has been shown to exacerbate T cell dysfunction. In the context of allogeneic transplantation, 
overexpression or agonism of these signaling pathways led to allograft tolerance, whereas absence 
or blockade led to accelerated rejection and lethality in mice (2–4). Several studies have shown that 
blocking IC interactions restored and/or enhanced T cell effector function (5–7). However, it is also 
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known that CD4+ and CD8+ T cells  expressing multiple IC during 
a normal response are not necessarily functionally compromised, 
but rather represent a phase of T cell activation (8), and that 
these molecules serve a costimulatory role in T  cell activation 
(9–12). In addition, expression of PD-1, TIM-3, and LAG-3 has 
been associated with activation and differentiation (13, 14), with 
reports suggesting that certain differentiation stages, effector 
memory (EM) in particular, correlate with increased function 
(10, 15).
Immune checkpoint-expressing CD8+ T cells isolated from 
HIV-infected patients can be associated with both increased 
or decreased cytotoxicity and viral load (12, 16, 17). In can-
cer, several groups have shown that IC blockade can restore 
antitumor immunity in T cells (7, 18), providing justification 
for targeting these molecules in the clinic (19, 20). However, 
it has also been reported that high expression of PD-1 on 
CD8+ tumor infiltrating lymphocytes correlates with antitumor 
specificity and reactivity (21). These paradoxical findings 
indicate that the context in which IC expression is analyzed 
can lead to variable predictions of T cell function. Previous 
in  vitro studies analyzing IC expression have implemented 
CD3/CD28 cross-linking for T cell activation (13), which, 
while informative, excludes the impact of IC ligands and 
soluble factors from viable antigen presenting cells. In addition, 
extensive studies have focused on IC expression and function 
of CD8+ T cells with less known regarding IC expression on 
CD4+ T cells; and while CD8+ T cells are major drivers of viral 
and tumor clearance, CD4+ T  cell help plays a major role in 
these responses. An analysis of IC expression on both CD4+ 
and CD8+ T cell expression could help optimize therapeutic 
IC blockade (or agonism). Here, we employ a modification of 
the mixed lymphocyte reaction (MLR) to dissect the differ-
ences in IC expression levels and kinetics on CD4+ and CD8+ 
T cells to define expression patterns during a physiological 
immune response. We report that expression of PD-1, LAG-3, 
and TIM-3 coincides with T cell activation and function, but 
these molecules are differentially expressed on CD4+ and CD8+ 
T cells. In addition, CD4+ T cells undergoing proliferation that 
express PD-1 often exhibit lower expression of TIM-3, while 
TIM-3 expressing CD8+ T cells have reduced PD-1 expres-
sion. These differences extend to cytokine production in that 
IC expression differs between cytokine-producing CD4+ and 
CD8+ T cells. Lastly, we find that CD4+ and CD8+ T cells exhibit 
different memory T cell phenotypes depending on which of 
these molecules are expressed.
MaTerials anD MeThODs
Primary cells
Purified human pan T cells from healthy donors were purchased 
from Biological Specialty Corporation (Colmar, PA, USA). T cells 
were confirmed to be >95% CD3+ by flow cytometry. Human 
monocyte-derived dendritic cells (DCs) from healthy donors 
were purchased from Astarte Biologics (Bothell, WA, USA) and 
confirmed to be >90% CD11c+, and >90% CD83+, CD86+, and 
HLA-DR+ after activation.
Mixed lymphocyte reaction
T cells and DCs were cultured in complete media consisting of 
RPMI 1640 with Glutamax (Life Technologies, Grand Island, 
NY, USA), supplemented with 5% heat inactivated human serum 
(Sigma, St. Louis, MO, USA). DC were cultured overnight with 
500 U/mL each of recombinant IL-4 and GM-CSF (Peprotech, 
Rocky Hill, NJ, USA) and matured with 1000 U/mL recombinant 
IFN-γ (Peprotech) and 1 ng/mL LPS (Sigma). Prior to coculture 
with DC were tested for maturation status by CD83, CD86, and 
HLA-DR expression by flow cytometry and IL-12 production 
by ELISA (R&D Systems, Minneapolis, MN, USA). T cells were 
labeled with violet proliferation dye 450 (BD) according to the 
manufacturer’s instructions. T cells were cultured with DC at a 
10:1 ratio, incubated at 37°C for the indicated timepoints, and 
analyzed for proliferation and activation by flow cytometry. 
Supernatants were collected and cytokines were measured by 
multiplex analyses (MesoScale Discovery, Rockville, MD, USA). 
For ELISPOT analysis, cells were collected on day 6 of MLR 
and analyzed for IFN-γ spot production using pre-coated plates 
(MabTech, Cincinnati, OH, USA). For intracellular detection of 
cytokines, cells were collected on day 6 of the MLR and treated 
with PMA (Sigma), ionomycin (Sigma), and GolgiPlug (BD, San 
Jose, CA, USA) for 6 h prior to addition of antibodies for flow 
analysis.
Flow cytometry
All cells were labeled with live/dead dye near infra red (Life 
Technologies) for dead cell exclusion and treated with Fc Block 
(Miltenyi, San Diego, CA, USA) prior to staining with fluores-
cently labeled antibodies. Anti-human antibodies used for DC 
staining were anti-CD83 PE (Biolegend, San Diego, CA, USA), 
anti-CD86-PE-Cy7 (Biolegend), anti-HLA-DR V450 (BD), and 
anti-CD11c APC (BD). Antibodies used in the T cell characteri-
zation were anti-LAG-3 FITC (Novus, Littleton, CO, USA), anti-
PD-1 PerCP-Cy5.5, anti-CD3 Alexa700, anti-CD4 Brilliant Violet 
650, anti-CD8 Brilliant Violet 570, anti-IFN-γ PE, anti-IL-5, 
anti-CD62L PE, and anti-CD45RA Alexa700 (all, Biolegend), 
anti-CD25 PE, and anti-IFN-γ PE-Cy7, anti-IL-4 PE-Cy7 (all 
BD), and anti-TIM-3 APC (R&D Systems). Surface staining and 
intracellular staining was performed using Cytofix/Cytoperm™ 
Plus kit (BD) according to the manufacturer’s instructions. Data 
acquisition was performed using the LSRFortessa flow cytometer 
(BD). Data analysis was performed with FlowJo version 9 (Tree 
Star, Inc., Ashland, OR, USA).
Quantification and statistical analysis
For all markers analyzed by flow cytometry, isotype controls 
were used to establish gates by setting gates between 0.5 and 1% 
positive events. Gates were drawn around each cell division as 
determined by violet proliferation dye dilution, and subsequent 
populations were analyzed for expression of CD25, PD-1, LAG-
3, and TIM-3. Quantifications were made based on data gener-
ated from FlowJo, and statistical analysis was performed using 
GraphPad Prism version 6. Statistical significance was deter-
mined using two-tailed paired t-test (Holm–Sidak) and two-way 
ANOVA (Dunnet’s). Correlation coefficients were determined 
using two-tailed paired monotonic analysis (Spearman).
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resUlTs
Differential Kinetics of immune 
checkpoint Molecule expression on 
Primed T cell Populations
To analyze T cell activation and kinetics of IC expression in an 
acute primary response, purified pan T cells from four different 
donors were cultured with allogeneic DC and analyzed at vari-
ous time points. We chose to mature the DC prior to addition 
to MLR to maximally activate the T cells. As mentioned in 
Section “Materials and Methods,” we confirmed activation by 
upregulation of CD83, CD86, and HLA-DR, as well as produc-
tion of IL-12p40 and IL-12p70 (Figures S1A,B in Supplementary 
Material). T cells were cultured with DC and gated on CD4+ 
and CD8+ T cells for analysis. As expected, both CD4+ and 
CD8+ T  cells exhibited progressively increasing proliferation 
(Figure  S1C in Supplementary Material) with the majority 
of T cells divided after 7  days and minimal proliferation by 
T cells cultured alone. Longitudinal analyses of supernatants 
collected from these cultures showed levels of TNF-α, IL-5, 
and IL-13 increased over time with steady levels of IFN-γ up 
to day 7 of MLR, while T cells alone did not produce detect-
able levels of cytokine (Figure  1A), as was the case for DC 
cultured alone (data not shown). Subsequent analyses of the 
T cells were performed on day 6 of MLR given that proliferation 
and cytokine production were measureable and still increasing, 
thus capturing T cells approaching peak activation. ELISPOT 
analysis showed cells actively producing IFN-γ when cultured 
with allogeneic DC, whereas T cells alone exhibited little to 
no spots (Figure 1B). We wanted to confirm these findings by 
intracellular staining for cytokine. A population of CD4+ and 
CD8+ T cells that produced IFN-γ, but not IL-5, was observed 
when cultured in absence of DCs, presumably in response to 
the PMA/ionomycin stimulation. In the undivided population, 
there was a subset observed in both CD4+ and CD8+ T cells 
that produced IFN-γ or IFN-γ and IL-5 together with very few 
producing IL-5 alone. The dual-cytokine-producing population 
was markedly increased on the divided population for both 
CD4+ and CD8+ T cells (Figure  1C). Together, these data 
demonstrate that the T cells are activated and likely the main 
source of cytokine measured in the supernatant of the MLR, 
thus showing that both CD4+ and CD8+ T cells are primed 
and functional after 6  days of stimulation by allogeneic DC. 
Additionally, we show that, although the allogeneic DC used as 
stimulators were activated with LPS and IFN-γ and produced 
IL-12, they did not polarize the T cells toward Type 1 or Type 2, 
given that both Th1 and Th2 cytokines were observed.
We next performed a detailed kinetics study of IC expres-
sion on activated T cells by flow cytometry (complete gating 
strategy shown in Figure S2 in Supplementary Material). By 
6  days after stimulation, nearly all dividing CD4+ and CD8+ 
cells expressed activation marker CD25 (>95%), whereas the 
non-dividing CD4+ and CD8+ populations had a much lower 
frequency of CD25+ cells (26.6 ± 2.2 and 12.3 ± 1.2%, respec-
tively) and lower overall mean fluorescence intensity (MFI) 
as shown in Figure  2 and Table  1. The frequency of CD25+ 
CD4+ T cells was significantly higher than that of CD25+ CD8+ 
(Figures 2A,B; Table 1); however, due to lack of proliferation 
and expression of other IC markers, these cells are unlikely 
to be responders. PD-1 expression was detectable in a small 
population of non-dividing cells (<15%), with even less or no 
LAG-3 and TIM-3 expressed in the population of non-dividing 
cells. Expression of PD-1, LAG-3, and TIM-3 was largely 
restricted to dividing cells, similar to CD25 (Figures  2A,B; 
Table  1), albeit at different levels between CD4+ and CD8+ 
T cells as well as within each population. On CD4+ T cells, PD-1 
expression was higher (61.4 ± 6.2%) compared to CD8+ T cells 
(31.0 ± 7.2%). Conversely, CD4+ expression of TIM-3 was lower 
(53.9 ± 4.9%) compared to TIM-3 expression on CD8+ T cells 
(75.9 ± 6.2%). LAG-3 expression on CD4+ (38.8 ± 3.8%) was 
lower than PD-1 and TIM-3; however, LAG-3 expression on 
CD8+ (49.6 ± 15.2%) varied between donors with no significant 
trend observable. Expression levels of each IC on CD4+ and 
CD8+ T cells across four donors are summarized in Table  1. 
This heterogeneity of IC expression between CD4+ and CD8+ 
T cells was evident even though analysis was restricted to 
dividing cells that were CD25+ indicating all were activated. 
To better understand the relationship between cell division and 
expression of PD-1, LAG-3, and TIM-3 during T cell activation, 
further analysis of IC molecule expression was performed by 
gating on iterative population doublings based on proliferation 
dye dilution over the course of the 6-day culture. As shown in 
Figure 2C, both CD4+ and CD8+ T cells exhibited MFI of each 
IC molecule in correlation with the number of cell divisions, 
i.e., the more a T cell had divided, the higher the expression of 
PD-1, LAG-3, and TIM-3, coinciding with the same expression 
kinetics as CD25. Interestingly, the MFI of CD25 and PD-1 was 
consistently higher on CD4+ T cells compared to CD8+ T cells, 
whereas the MFI of LAG-3 and TIM-3 was higher on CD8+ 
T cells compared to CD4+. The broad distribution of IC expres-
sion observed on dividing CD4+ and CD8+ T cells prompted us 
to evaluate co-expression between these molecules. Upon closer 
examination of CD25+ proliferating cells, PD-1 presented with 
differential expression between CD4+ and CD8+ T cells. The 
majority of CD25-expressing CD4+ T cells also expressed PD-1 
(66%), whereas of the CD25+ CD8+ T cells, only 30% expressed 
PD-1 (Figure  2D). Gating on CD25+ PD-1+ double positive 
CD4+ T cells, we found that 58% expressed LAG-3 and 37% 
expressed all four. CD25+ PD-1+ double positive CD8+ T cells 
had even higher expression of the other two IC, with ~95% 
expressing LAG-3 and ~75% expressing TIM-3 (Figure  2D). 
To  determine the kinetics of expression of these markers 
throughout the priming phase, we performed longitudinal 
analyses of activated T cells in the MLR. Although by day 4, very 
few cells had divided (Figure S1C in Supplementary Material), 
we found that within the population of the dividing cells, nearly 
all expressed CD25 and that this expression was sustained 
through day 7 (Figure  2E). A subset of both dividing CD4+ 
and CD8+ cells upregulated TIM-3, LAG-3, and PD-1 at day 
4; however, while we showed that the number of dividing cells 
increased over time, PD-1 expression began to decrease by day 
6 with a more significant reduction observed on CD8+ T cells 
(Figure 2E). LAG-3 expression also decreased by day 7 on CD8+ 
T cells, but not on CD4+, while TIM-3 expression remained 
FigUre 1 | T cells stimulated by allogeneic Dc do not exhibit Th1/Th2 bias in cytokine production. Human pan T cells from multiple donors were cultured 
in vitro with allogeneic DC that had been activated with LPS and IFN-γ. (a) Time-course analysis by MSD of cytokine levels accumulated in MLR supernatants; 
panels clockwise from the left: IFN-γ, TNF-α, IL-5, and IL-13; filled shapes represent T cells cultured with DC, open shapes represent T cells cultured alone (three 
donors). Cells collected from day 6 of MLR were analyzed for (B) IFN-γ spot forming units by ELISPOT or (c) CD4+ and CD8+ production of IFN-γ and IL-5 by flow 
cytometry. Contour plots representative of three independent experiments after fluorescence compensation and gating on live cells → singlets → CD3+ 
T cells → CD4+ versus CD8+ T cells.
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stable on both subsets (Figure 2E). These findings indicate that, 
within the context of an in  vitro allogeneic response, PD-1, 
LAG-3, and TIM-3 expression coincide with T cell activation, 
but show that the expression kinetics differ between CD4+ 
and CD8+ T cells. Responding CD8+ T  cells exhibited lower 
initial PD-1 expression compared to CD4+ T cells, with more 
rapid downregulation further highlighting the heterogeneity 
of IC expression in the responding CD4+ and CD8+ T cell 
populations.
activated cD4+ and cD8+ T cells  
Differ in expression Patterns  
of immune checkpoint Molecules
Having shown that activated and proliferating T cells expressed 
IC to varying degrees as well as with differential kinetics, we were 
then interested in analyzing IC expression in association with 
cytokine production. Based on the cytokine milieu measured in 
the MLR (Figure  1A), we focused our subsequent analyses on 
FigUre 2 | activated T cells express PD-1, lag-3, and TiM-3.  
(Continued)
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Human pan T cells were stimulated with allogeneic DC for 6 days. (a) Representative flow cytometry histograms of CD4+ and CD8+ T cells gated on the responding 
(divided) or non-responding (undivided) population based on proliferation dye dilution, and analyzed for CD25, PD-1, LAG-3, and TIM-3 expression (black lines) 
compared to isotype (shaded gray). (B) Graphical representation of IC expression on non-responding (undivided) and responding (divided) CD4+ (black bars) and 
CD8+ T cells (gray bars). Data pooled from four independent experiments. *p < 0.0001, two-way ANOVA (Dunnet’s). (c) Representative gating strategy of CD25, 
PD-1, LAG-3, and TIM-3 expression within each cell division (top panels). Graphical analyses depicting expression of each IC for CD4+ (open circles) and CD8+ 
(closed circles) T cells by geometric MFI for two donors (bottom panels). (D) Representative dot plots of co-expression of CD25, PD-1, TIM-3, and LAG-3 on CD4+ 
and CD8+ T cells. Plots of TIM-3 versus LAG-3 were drawn from CD25+ PD-1+ gates. Data are representative of three independent experiments. (e) Trendlines 
depicting expression of CD25 (filled squares), PD-1 (open diamonds), LAG-3 (filled circles), and TIM-3 (open triangles) on dividing CD4+ and CD8+ T cells over time. 
Data representative of three different donors at each time point compiled from two independent experiments.
FigUre 2 | continued
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IFN-γ and IL-5 and observed that cytokine production was asso-
ciated with high expression of PD-1 and LAG-3 for both CD4+ 
and CD8+ T cells. However, expression of TIM-3 was significantly 
decreased on cytokine-producing CD4+ T cells compared to 
cytokine-producing CD8+ T cells (Figures 3A,B). As shown in 
TaBle 1 | immune checkpoint expression on dividing and non-dividing 
cD4+/cD8+ T cells.
cD4 cD8
Undivided (mean ± seM)
CD25 28.45 ± 1.83 15.10 ± 1.84
30.96 ± 1.25 12.76 ± 0.61
26.37 ± 0.26 9.09 ± 0.37
20.67 ± 0.12 12.20 ± 0.81
PD-1 5.48 ± 0.10 7.22 ± 0.08
10.54 ± 0.19 12.40 ± 0.49
7.92 ± 0.25 13.23 ± 0.84
8.95 ± 0.41 16.90 ± 0.71
LAG-3 2.31 ± 0.15 1.21 ± 0.15
1.06 ± 0.07 2.96 ± 0.74
3.84 ± 0.08 1.78 ± 0.29
3.42 ± 0.19 4.39 ± 0.61
TIM-3 1.01 ± 0.13 1.78 ± 0.23
1.04 ± 0.14 1.54 ± 0.08
0.72 ± 0.10 1.30 ± 0.28
0.07 ± 0.06 1.14 ± 0.16
Divided (mean ± seM)
CD25 97.19 ± 0.15 97.44 ± 0.20
97.68 ± 0.03 96.45 ± 0.15
99.17 ± 0.48 97.47 ± 0.59
94.43 ± 1.05 85.00 ± 2.02
PD-1 47.72 ± 1.52 21.22 ± 1.38
59.46 ± 0.73 24.19 ± 1.28
60.50 ± 2.14 26.13 ± 1.60
78.03 ± 2.08 52.47 ± 0.45
LAG-3 30.89 ± 2.07 19.91 ± 0.42
37.72 ± 1.73 27.12 ± 2.28
37.53 ± 1.27 71.00 ± 1.16
49.13 ± 1.03 80.20 ± 0.79
TIM-3 57.84 ± 2.44 80.12 ± 0.94
61.63 ± 2.93 86.74 ± 0.59
39.40 ± 1.88 58.03 ± 2.28
56.57 ± 1.66 78.87 ± 1.30
Human pan T cells were stimulated with allogeneic DC for 6 days. CD4+ and CD8+ 
T cells were analyzed by flow cytometry and gated on responding (divided) or non-
responding (undivided) population based on proliferation dye dilution, and analyzed 
for CD25, PD-1, LAG-3, and TIM-3 expression. Mean and SEM were calculated from 
three biological replicates per donor. Data from four donors are shown.
the previous section, the frequency of TIM-3-expressing CD8+ 
T cells was consistently higher compared to the frequency of 
CD4+ T cells from each donor tested, whereas PD-1 appears to 
be expressed on CD4+ at a slightly higher frequency compared 
to CD8+ T cells. Figure 3C illustrates the relationship between 
expression patterns of each IC molecule on CD4+ and CD8+ T cells. 
A negative correlation was observed in PD-1 and TIM-3 expres-
sion, in which cells that expressed high PD-1 had lower TIM-3 
expression and cells with low PD-1 and higher TIM-3 [Spearman 
test r value (r) in the pair comparison was 0.90, p < 0.0001]. Of 
note, PD-1hiTIM-3lo expression was largely restricted to CD4+ T 
cells, whereas CD8+ T cells were predominantly PD-1loTIM-3hi 
(Figure  3C). No correlation was observable with LAG-3 and 
TIM-3 or PD-1 (r = −0.05, p = 0.81 and r = −0.01, p = 0.96, 
respectively). Taken together, these results show that although 
PD-1, TIM-3, and LAG-3 are upregulated on activated T cells, 
the expression pattern of these molecules, in particular PD-1 and 
TIM-3, differs between CD4+ and CD8+ T cells.
immune checkpoint Positive cells exhibit 
Differential Memory Phenotype between 
cD4+ and cD8+ T cells
There are several possible outcomes during T cell response to 
antigen including, but not limited to, differentiation into subsets 
with defined functions such as effector cells, EM cells, or central 
memory (CM) cells. To further understand the difference in IC 
expression between CD4+ and CD8+ T cells, each subset was ana-
lyzed for phenotypic memory T cell markers by flow cytometry. 
To ensure exclusion of naive/non-responding cells, only prolifer-
ating cells were analyzed. Nearly all responding CD4+ and CD8+ 
T cells exhibited either a CM phenotype (CD62L+ CD45RA−) or 
effector/EM (CD62L− CD45RA−) (Figures 4A,B), independent 
of the IC expression profile. However, some variation was evi-
dent when looking at IC expression on subsets (Figure 4C). We 
observed a slight increase in CM on PD-1- and TIM-3-expressing 
CD4+ T cells (55.6% ± 1.4 and 55.3% ± 2.4, respectively) com-
pared to LAG-3-expressing CD4+ (48.2% ±  4.7). LAG-3- and 
PD-1-expressing CD8+ T cells favored an EM phenotype with 
less than half the cells exhibiting a CM phenotype (38.1% ± 4.2 
and 43.8% ± 1.5, respectively). CD8+ T cells expressing TIM-3 
had significantly higher frequencies of CM cells compared to 
the other two IC-expressing CD8+ T cell subsets/populations 
(52.1% ±  0.9). Distribution of memory subsets on IC-positive 
cells differed between CD4+ and CD8+ T cells themselves. There 
were significantly more CD4+ T cells bearing a CM phenotype 
7Sabins et al. Differential Immune Checkpoint Marker Expression
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in LAG-3 and PD-1-expressing populations compared to CD8+ 
T cells expressing LAG-3 and PD-1 (Figure  4C). However, 
CD4+ and CD8+ T cells that expressed TIM-3 exhibited similar 
ratios between CM and EM with a slight skewing toward CM 
(Figure 4C). Overall, these data reflect another qualitative dif-
ference between CD4+ and CD8+ T cells in their IC expression 
described here in relation to memory phenotype.
DiscUssiOn
Over the last decade, several molecules have been shown to be 
expressed on T cells isolated from patients suffering from chronic 
viral infection or tumor burden. Poor immune function has been 
associated with these T cells, thus classifying them as being 
“exhausted.” Clinical studies evaluating blockade of individual IC 
molecules, such as PD-1, have shown promising results. In one 
trial, a response rate of 20–25% was reported for patients includ-
ing those with renal cell carcinoma, melanoma, non-small cell 
lung carcinoma, and prostate cancer (19). In a separate clinical 
trial, a 38% response rate was reported for patients with advanced 
melanoma after treatment with an anti-PD-1 antibody (20). As a 
means to further increase the response rate, a logical next step 
is the exploration of potential combinatorial treatments that 
target multiple IC. To date, concurrent targeting of CTLA-4 and 
PD-1 in the clinic with antagonist antibodies exhibited slightly 
enhanced therapeutic efficacy compared to mono-therapy with 
either agent (22), thus encouraging investigation of additional 
combination treatments involving other IC molecules. Indeed, 
a recent study showed that in a preclinical model, resistance 
to anti-PD-1 treatment could be overcome by blockade to 
additional IC, such as TIM-3. The authors also reported that 
patients who became resistant to anti-PD-1 treatment exhibited 
upregulation of TIM-3 and other IC (23).
Targeting of IC may lead to pleiotropic effects due to the 
diversity of cell populations that express these molecules. While 
expression of PD-1 and TIM-3 on CD4+ and CD8+ T cells has 
been reported, it has mainly been in the context of being a phe-
notypic indicator of T cell exhaustion (17, 24, 25); in the context 
of in  vitro allogeneic T cell priming, the expression of TIM-3 
and PD-1 is not uniformly high. One possible explanation for 
this is that these two molecules are reciprocally expressed, 
meaning that they share some mechanism that regulates their 
expression ensuring that when PD-1 is upregulated TIM-3 is 
not, and vice  versa. This mechanism of regulation is feasible 
but would not necessarily apply directly following priming. As 
shown in Figure 2, PD-1 is expressed equivalently on CD4+ and 
CD8+ T cells for the first few rounds of division, which correlates 
with the time period immediately following antigen encounter. 
During this same window of time, the TIM-3 expression profile 
already differs between CD4+ and CD8+ T cells, indicating that 
very early after antigen encounter, both PD-1 and TIM-3 are 
upregulated to a greater extent on CD8+ T cells. Based on the 
FigUre 3 | Differential expression of immune checkpoints between cD4+ and cD8+ T cells. Human pan T cells were stimulated with allogeneic DC for 
6 days, as done in Figure 2, and analyzed for intracellular cytokines as done in Figure 1. (a) Gates were drawn on IFN-γ or IL-5-positive CD4+ and CD8+ T cells 
and expression of TIM-3, LAG-3, and PD-1 (black lines) is shown compared to isotype control (shaded gray) as percent positive events. (B) Graphical representation 
LAG-3, PD-1, and TIM-3 expression levels on IFN-γ and IL-5 producing CD4+ (black) and CD8+ (gray) T cells. Data are mean ± SEM compiled from three donors. 
*p < 0.005, **p < 0.001, two-tailed t-test (Holm–Sidak). (c) Expression of PD-1, LAG-3, and TIM-3 was analyzed on activated CD4+ (closed circles) or CD8+ (open 
circles) T cells. TIM-3 expression was compared to PD-1 (left panel), LAG-3 (center panel), and PD-1 expression was compared to LAG-3 (right panel). Spearman’s 
rank correlation coefficients r, along with 95% confidence intervals (MIN and MAX), are shown. Data compiled from four different donors conducted in three 
independent experiments.
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data shown herein, both CD4+ and CD8+ T cells immediately 
upregulate PD-1 expression, but in contrast to CD8+ T cells, 
CD4+ T cells maintain lower TIM-3 expression levels while 
increasing PD-1. This may be in response to soluble factors 
being released during the MLR, as it has been recently shown 
that γc cytokines can differentially regulate TIM-3 and PD-1 
FigUre 4 | T cells expressing immune checkpoint molecules exhibit central and effector memory phenotypes. Human pan T cells were stimulated with 
allogeneic DC for 6 days, as done in Figure 2. LAG-3, PD-1, and TIM-3 expressing CD4+ and CD8+ T cells were subsequently analyzed for CD45RA and CD62L 
expression. (a) Representative flow cytometric contour plots, gated on dividing CD4+ or CD8+ T cells, depicting quadrant gates separating different T cell memory 
subsets. (B) Pie charts quantifying T cell memory subsets within each immune checkpoint molecule expressing population. (c) Bar graph comparing frequencies of 
CD62L+ CD45RA− cells within each immune checkpoint molecule expressing population. Data are mean ± SEM compiled from three donors. *p < 0.05, **p < 0.01, 
two-way ANOVA (Dunnet’s).
9Sabins et al. Differential Immune Checkpoint Marker Expression
Frontiers in Immunology | www.frontiersin.org June 2016 | Volume 7 | Article 221
expression on HIV-specific T cells (26). Future studies would 
include testing the impact of blocking individual γc cytokines 
(i.e., IL-2, IL-7, IL-15, and IL-21) in the MLR on IC expression. 
Another possible explanation is that TIM-3 and PD-1 are inde-
pendently regulated, but have different expression kinetics. This 
could suggest that TIM-3 and PD-1 mediate non-overlapping 
functions; though PD-1 is well documented to be a negative 
regulator in T cell function, TIM-3 may play a different role not 
limited to downmodulation of T cell activity. Note that cytokine 
production and proliferation continue throughout the culture 
period, suggesting T cell functionality is maintained. While 
these studies examined a limited cohort of samples (n =  4), 
the data suggest that activated CD4+ T cells exhibit higher PD-1 
expression compared to CD8+ T cells with comparably lower 
levels of TIM-3 expression, while the inverse expression pattern 
is observed on activated CD8+ T cells (i.e., higher TIM-3 and 
lower PD-1). Although the functional implications of these 
findings are beyond the scope of this report, results published 
by others have been mixed regarding expression of IC and 
T cell function. One study has shown that, in the context of 
Hepatitis B infection, inhibitory CD4+ T cells maintained high 
PD-1 expression with low TIM-3 (27). However, another group 
claimed that increased numbers of CD4+ PD-1highTIM-3negative 
T  cells in follicular lymphoma patients did not correlate to 
clinical outcome and that these cells were in fact still functional. 
In the same study, CD4+ PD-1lowTIM-3positive T cells displayed 
reduced cytokine production and signal transduction (28). 
While we did not observe differences in the level of cytokine 
production between IC-expressing subsets, our data indicate 
that cytokine-producing CD8+ T cells are higher in TIM-3 
expression. However, this observation was made in the context 
of an acute primary immune response and does not reflect the 
conditions of chronic antigen stimulation. In another report, 
it has shown that virus-specific CD8+ T cells expressing high 
TIM-3 were, in fact, less functional compared to TIM-3low CD8+ 
T cells (29).
Following an acute infection and subsequent clearing of the 
pathogen, T cells enter a contraction phase in which the majority 
of the cells undergo apoptosis, while a small subset become mem-
ory T cells that are able to persist long term even in the absence 
of further antigen stimulation. Upon re-encounter with cognate 
antigen, memory T cells quickly re-activate, proliferate, and 
acquire effector functions (30). It has been shown that expression 
of PD-1, TIM-3, and LAG-3 is predominantly associated with an 
EM phenotype on CD8+ T cells (13, 14, 31); however, such infor-
mation regarding CD4+ memory T cells remains insufficient. In 
the studies reported herein, LAG-3, PD-1, and TIM-3 expressing 
CD4+ and CD8+ T cells encompass both EM and CM subsets as 
classified here by CD62L expression, a marker generally associ-
ated with CM when expressed on CD45RA− T cells (32). Using 
these criteria, PD-1, TIM-3, and LAG-3 were detectable on both 
EM and CM T cells. PD-1 and LAG-3 expression were associ-
ated with EM phenotype at a slightly higher frequency on CD8+ 
T cells. However, TIM-3 expression was more balanced between 
CM and EM populations for both CD4+ and CD8+ T cells. We 
acknowledge these as preliminary phenotypic observations, and 
more in-depth analyses involving additional memory markers, 
including but not limited to CCR7 and CD95, are required to 
gain a more complete definition of the cells. It is possible that the 
frequency of CM and effector/EM cells observed here constitute 
only a snapshot of the differentiation process occurring in a 
primary immune response (33). However, another possibility is 
that our MLR conditions are expanding existing cell populations 
of a particular memory phenotype (i.e., central or effector), rather 
than inducing differentiation. The higher CD62L expression 
observed on all IC-expressing CD4+ T cells may reflect a different 
stage in differentiation than CD8+ T cells. Alternatively, it has also 
been reported that CD4+ CD62L+ CM T cells can be converted 
to FoxP3+ T cells and that this may be a regulatory mechanism 
to control proliferation of effector T cells (34). In the context of 
the MLR, it is possible that IC-expressing CD4+ CM cells, fol-
lowing activation, can convert to regulatory T cells to control 
activated alloreactive CD8+ T cells. Further studies are necessary 
to discriminate these mechanisms and understand the potential 
role that IC plays in T cell differentiation, and vice versa, as well 
as immune regulation.
Downregulation of PD-1 on CD8+ T cells is associated with 
acute liver allograft rejection (35). In addition, negative signaling 
by TIM-3-expressing CD4+ T cells has been shown to confer pro-
tection of allogeneic liver transplants in mice (36, 37). An elegant 
and comprehensive review by McGrath and Najafian (38) outlines 
the roles of IC signaling in tolerance and applications targeting IC 
in transplantation, some already in advanced clinical trials (i.e., 
CTLA-4-Ig). There have been several groups exploring the use 
of other fusion proteins, including PD-L1-Ig and B7-H4-Ig, in 
preclinical allograft models. The use of agonistic IC mAb (i.e., 
anti-BTLA) and stable IC ligands (i.e., galectin-9) has also shown 
promising results in various transplant models. However, there is 
still much to be understood before any of these IC therapeutics 
can be applied in the clinic.
Overall, our in  vitro findings show that there are differ-
ences in expression of IC molecules between CD4+ and CD8+ 
T  cells and suggest that further studies are needed to under-
stand the functional significance of IC expression patterns 
between CD4+ and CD8+ T cells. Therapeutic targeting of IC 
molecules becomes a challenge with mixed cell populations 
due to broad expression patterns of some IC molecules on 
other cell types. For example, TIM-3 is known to be expressed 
on innate cells, including DCs, macrophages, and NK cells 
(39–42); thus, TIM-3 blockade likely would not solely target 
exhausted T cells. Expression of IC on cell types other than 
T cells would act as potential “sinks” for any therapeutic target-
ing of these molecules, resulting in dosing inconsistencies as 
well as potential unexpected on-target (but off-T-cell) effects 
on other IC-expressing cell populations. Given the diverse 
distribution of IC expression on T cells and other cell types, one 
way to enhance cell-specific IC targeting would be to include 
a T cell-specific, or even CD4+ or CD8+ specific, moiety in 
a therapeutic, thereby increasing the likelihood of binding 
to IC on a particular cell type. Likewise, if the intent was to 
target non-T cells, alternate cell-specific (e.g., CD11c) targeting 
domains could be included in a therapeutic. Another strategy 
would be to administer different IC blockade (or agonist) to 
patients depending on their disease state, since kinetics of the 
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